米非司酮在子宫肌瘤合并贫血术前预处理中的应用价值.pdfVIP

窑临床研究 窑 中国医药导报 2014年9月第 11卷第25期 米非司酮在子宫肌瘤合并贫血术前预处理中的 应用价值 徐凤娟 徐 燕 钱晓红 余婷婷 苏州大学附属太仓医院妇产科袁江苏太仓 215400 [摘要] 目的探讨米非司酮在子宫肌瘤合并中重度贫血患者术前预处理中的价值遥 方法 选择2010年 1月~ 2013年 12月苏州大学附属太仓医院子宫肌瘤合并中重度贫血患者93例为研究对象袁将其分为用药组渊61例冤 和输血组渊32例冤遥给予用药组患者口服米非司酮 12.5mg袁每日 1次袁同时辅助以口服琥珀酸亚铁袁待贫血纠正后 住院手术治疗曰输血组患者未用药袁直接输血后手术治疗遥 比较分析两组患者的手术时间尧术中出血量尧住院费 用尧住院天数尧术后发热及切口渗液等情况遥 结果 治疗后袁用药组患者的血红蛋白由渊78.46依10.09冤g/L上升到 渊104.23依19.71冤g/L袁差异有统计学意义渊P约0.05冤曰用药组的血清雌二醇尧黄体酮以及促黄体激素水平显著低于输 血组袁差异有统计学意义渊P约0.05冤遥输血组手术时间尧住院天数尧住院费用尧术后病率明显高于用药组袁差异有统 计学意义渊P 约0.05冤曰用药组的总有效率为95.08%渊58/61冤袁显著高于输血组的81.25%渊26/32冤袁差异有统计学意 义渊字2=4.59袁P约0.05冤遥 治疗期间袁两组不良反应主要为恶心尧乏力及眩晕袁输血组不良反应发生率为9.38%袁用药 组为6.56%袁两组比较袁差异无统计学意义渊字2=0.24袁P 跃0.05冤遥 结论术前短期应用小剂量米非司酮及口服补血 药可以有效纠正子宫肌瘤合并中重度贫血者的贫血状态袁降低医疗费用及手术对患者的损伤袁同时节省血源以 缓解用血紧张矛盾遥 [关键词] 子宫肌瘤曰贫血曰术前用药 [中图分类号] R711.74 [文献标识码]A [文章编号] 1673-7210渊2014冤09渊a冤-0054-04 The value of the Mifepristone in preoperative pretreatment of uterine fi鄄 broidsmerger moderately severeanemia XU Fengjuan XU Yan QIANXiaohong YUTingting Department of Obstetrics and Gynecology, Taicang Hospital of Suzhou University, Jiangsu Province, Taicang 215400, China [Abstract] Objective To investigate the preoperative value of Mifepristone in treatment of uterine leiomyoma with se鄄 vere anemia.Methods 93 patients with uterinefibroids and moderate to severe anemiafromJanuary 2010 to December 2013 in Taicang Hospital of Suzhou University were selected as study objects, and they were divided into treatment group (61 cases) and blood transfusion group (32 cases). Patients of the treatment group were accepted mifepristone 12.5mg orally, 1time per day, and aided by oral amber acid ferrous at the same time, they were